|
1
|
Anderson WF, Katki HA and Rosenberg PS:
Incidence of breast cancer in the United States: current and future
trends. J Natl Cancer Inst. 103:1397–1402. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marshall E: Breast cancer. Dare to do
less. Science. 343:1454–1456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Clarke R, Leonessa F, Welch JN and Skaar
TC: Cellular and molecular pharmacology of antiestrogen action and
resistance. Pharmacol Rev. 53:25–71. 2001.PubMed/NCBI
|
|
4
|
Lønning PE: Aromatase inhibitors in breast
cancer. Endocr Relat Cancer. 11:179–189. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nabha SM, Glaros S, Hong M, Lykkesfeldt
AE, Schiff R, Osborne K, et al: Upregulation of PKC-delta
contributes to antiestrogen resistance in mammary tumor cells.
Oncogene. 24:3166–3176. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shou J, Massarweh S, Osborne CK, Wakeling
AE, Ali S, Weiss H and Schiff R: Mechanisms of tamoxifen
resistance: increased estrogen receptor-HER2/neu cross-talk in
ER/HER2-positive breast cancer. J Natl Cancer Inst. 96:926–935.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kaufmann M, Bajetta E, Dirix LY, Fein LE,
Jones SE, Zilembo N, et al: Exemestane is superior to megestrol
acetate after tamoxifen failure in postmenopausal women with
advanced breast cancer: results of a phase III randomized
double-blind trial. The Exemestane Study Group. J Clin Oncol.
18:1399–1411. 2000.PubMed/NCBI
|
|
9
|
Benz CC, Scott GK, Sarup JC, Johnson RM,
Tripathy D, Coronado E, et al: Estrogen-dependent,
tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected
with HER2/neu. Breast Cancer Res Treat. 24:85–95. 1992. View Article : Google Scholar
|
|
10
|
Kurokawa H, Lenferink AE, Simpson JF,
Pisacane PI, Sliwkowski MX, Forbes JT, et al: Inhibition of
HER2/neu (erbB-2) and mitogen-activated protein kinases enhances
tamoxifen action against HER2-overexpressing, tamoxifen-resistant
breast cancer cells. Cancer Res. 60:5887–5894. 2000.PubMed/NCBI
|
|
11
|
Atanaskova N, Keshamouni VG, Krueger JS,
Schwartz JA, Miller F and Reddy KB: MAP kinase/estrogen receptor
crosstalk enhances estrogen-mediated signaling and tumor growth but
does not confer tamoxifen resistance. Oncogene. 21:4000–4008. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ashkenazi A, Pai RC, Fong S, Leung S,
Lawrence DA, Marsters SA, et al: Safety and antitumor activity of
recombinant soluble Apo2 ligand. J Clin Invest. 104:155–162. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takeda K, Stagg J, Yagita H, Okumura K and
Smyth MJ: Targeting death-inducing receptors in cancer therapy.
Oncogene. 26:3745–3457. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lawrence D, Shahrokh Z, Marsters S,
Achilles K, Shih D, Mounho B, et al: Differential hepatocyte
toxicity of recombinant Apo2L/TRAIL versions. Nat Med. 7:383–385.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chinnaiyan AM, Prasad U, Shankar S,
Hamstra DA, Shanaiah M, Chenevert TL, et al: Combined effect of
tumor necrosis factor-related apoptosis-inducing ligand and
ionizing radiation in breast cancer therapy. Proc Natl Acad Sci
USA. 97:1754–1759. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Keane MM, Ettenberg SA, Nau MM, Russell EK
and Lipkowitz S: Chemotherapy augments TRAIL-induced apoptosis in
breast cell lines. Cancer Res. 59:734–741. 1999.PubMed/NCBI
|
|
17
|
Singh TR, Shankar S, Chen X, Asim M and
Srivastava RK: Synergistic interactions of chemotherapeutic drugs
and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2
ligand on apoptosis and on regression of breast carcinoma in vivo.
Cancer Res. 63:5390–5400. 2003.PubMed/NCBI
|
|
18
|
Kourousis C, Kakolyris S, Androulakis N,
Heras P, Vlachonicolis J, Vamvakas L, et al: Salvage chemotherapy
with paclitaxel, vinorelbine, and cisplatin (PVC) in
anthracycline-resistant advanced breast cancer. Am J Clin Oncol.
21:226–232. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sledge GW Jr, Loehrer PJ Sr, Roth BJ and
Einhorn LH: Cisplatin as first-line therapy for metastatic breast
cancer. J Clin Oncol. 6:1811–1814. 1988.PubMed/NCBI
|
|
20
|
Lykkesfeldt AE and Briand P: Indirect
mechanism of oestradiol stimulation of cell proliferation of human
breast cancer cell lines. Br J Cancer. 53:29–35. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miller RP, Tadagavadi RK, Ramesh G and
Reeves WB: Mechanisms of cisplatin nephrotoxicity. Toxins.
2:2490–2518. 2010. View Article : Google Scholar
|
|
22
|
Ashkenazi A and Dixit VM: Death receptors:
signaling and modulation. Science. 281:1305–1308. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin J, Zhang Z, Zeng S, Zhou S, Liu BF,
Liu Q, et al: TRAIL-induced apoptosis proceeding from
caspase-3-dependent and -independent pathways in distinct HeLa
cells. Biochem Biophys Res Commun. 346:1136–1141. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Devarajan E, Sahin AA, Chen JS,
Krishnamurthy RR, Aggarwal N, Brun AM, et al: Down-regulation of
caspase 3 in breast cancer: a possible mechanism for
chemoresistance. Oncogene. 21:8843–8851. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fisher B, Dignam J, Bryant J, DeCillis A,
Wickerham DL, Wolmark N, et al: Five versus more than five years of
tamoxifen therapy for breast cancer patients with negative lymph
nodes and estrogen receptor-positive tumors. J Natl Cancer Inst.
88:1529–1542. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Berstein LM, Zheng H, Yue W, Wang JP,
Lykkesfeldt AE, Naftolin F, et al: New approaches to the
understanding of tamoxifen action and resistance. Endocr Relat
Cancer. 10:267–277. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Horwitz KB: When tamoxifen turns bad.
Endocrinology. 136:821–823. 1995.PubMed/NCBI
|
|
28
|
Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY,
Zhu Y, et al: Antiestrogen resistance in breast cancer and the role
of estrogen receptor signaling. Oncogene. 22:7316–7339. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yde CW, Gyrd-Hansen M, Lykkesfeldt AE,
Issinger OG and Stenvang J: Breast cancer cells with acquired
antiestrogen resistance are sensitized to cisplatin-induced cell
death. Mol Cancer Ther. 6:1869–1876. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Janicke RU, Sprengart ML, Wati MR and
Porter AG: Caspase-3 is required for DNA fragmentation and
morphological changes associated with apoptosis. J Biol Chem.
273:9357–9360. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yin S, Sethi S and Reddy KB: Protein
kinase Cδ and caspase-3 modulate TRAIL-induced apoptosis in breast
tumor cells. J Cell Biochem. 111:979–987. 2010. View Article : Google Scholar : PubMed/NCBI
|
